Form 4: RVMD Exec Sells Shares for Tax Obligations

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 5,367 shares of common stock to cover tax withholding obligations from RSU vesting.

Summary

• Stephen Michael Kelsey, President, Research and Development at Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• The transaction involved the disposition of 5,367 shares of common stock.
• The shares were sold at a price of $45.8249 per share.
• The sale occurred on September 16, 2025.
• The transaction was executed under a Rule 10b5-1 plan adopted on May 31, 2023, specifically to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Stephen Michael Kelsey beneficially owns 284,047 shares of common stock, which includes 84,000 restricted stock units.

Sentiment

Score: 5

Explanation: A routine insider sale for tax withholding purposes under a pre-arranged 10b5-1 plan is neutral in sentiment. It does not reflect a positive or negative view on the company's future prospects, but rather a standard compensation and tax management event.

Future Outlook

NA

Industry Context

This is a routine insider transaction for tax purposes and does not provide specific insights into broader industry trends or competitive landscape. Such sales are common for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: A minor dilution effect from the sale, but primarily a routine event for executive compensation and tax management, unlikely to have significant direct impact.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing reports a routine insider sale by an executive to cover tax obligations upon the vesting of restricted stock units, executed under a pre-arranged 10b5-1 plan. Such a transaction is not indicative of the executive's sentiment regarding the company's future performance and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should 'hold' their position and look for more substantive operational or financial news.

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, 10b5-1 Plan